Your browser doesn't support javascript.
loading
TET2 Deficiency Sets the Stage for B-cell Lymphoma.
Shingleton, Jennifer R; Dave, Sandeep S.
Afiliación
  • Shingleton JR; Cancer Genetics and Genomics Program, Duke Cancer Institute, Center for Genomic and Computational Biology, Duke University, Durham, North Carolina.
  • Dave SS; Cancer Genetics and Genomics Program, Duke Cancer Institute, Center for Genomic and Computational Biology, Duke University, Durham, North Carolina. sandeep.dave@duke.edu.
Cancer Discov ; 8(12): 1515-1517, 2018 12.
Article en En | MEDLINE | ID: mdl-30510015
ABSTRACT
TET2 is a well-established tumor suppressor in the context of myeloid malignancies, but its role in lymphoma development has been less clear. In this issue of Cancer Discovery, Dominguez and colleagues report that TET2 function is critical for germinal center exit and plasma cell differentiation, and its deficiency can lead to B-cell lymphoma phenotypes.See related article by Dominguez et al., p. 1632.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células B / Proteínas Proto-Oncogénicas Límite: Humans Idioma: En Revista: Cancer Discov Año: 2018 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células B / Proteínas Proto-Oncogénicas Límite: Humans Idioma: En Revista: Cancer Discov Año: 2018 Tipo del documento: Article